{
    "id": "dbpedia_8465_2",
    "rank": 12,
    "data": {
        "url": "https://patents.google.com/patent/EP1935412A3/en",
        "read_more_link": "",
        "language": "en",
        "title": "EP1935412A3 - Pharmaceutical composition containing 5-chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-yl]-1,3-dihydro-2H-benzimidazol-2-one and method of preparing same - Go",
        "top_image": "",
        "meta_img": "",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2006-12-13T00:00:00",
        "summary": "",
        "meta_description": "The present invention relates to a pharmaceutical composition, in the form of a tablet disintegrating in less than three minutes, comprising from 1% to 60% by weight of the active ingredient domperidone or a pharmaceutically acceptable salt thereof; from 20% to 90% by weight of at least one diluting agent with no known effect; from 0.01% to 5% of at least one wetting agent; from 0.1% to 15% by weight of at least one disintegrant; the percentages by weight being expressed relative to the total weight of said composition. The present invention also relates to the use of said pharmaceutical composition for the preparation of a medicament for treating and / or preventing nausea, vomiting, nausea and / or disorders of digestion and a method of preparing the same. an orodispersible tablet based on said pharmaceutical composition.",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://patents.google.com/patent/EP1935412A3/en",
        "text": "Pharmaceutical composition containing 5-chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-yl]-1,3-dihydro-2H-benzimidazol-2-one and method of preparing same Download PDF\n\nInfo\n\nPublication number\n\nEP1935412A3\n\nEP1935412A3 EP07123148A EP07123148A EP1935412A3 EP 1935412 A3 EP1935412 A3 EP 1935412A3 EP 07123148 A EP07123148 A EP 07123148A EP 07123148 A EP07123148 A EP 07123148A EP 1935412 A3 EP1935412 A3 EP 1935412A3\n\nAuthority\n\nEP\n\nEuropean Patent Office\n\nPrior art keywords\n\nbenzimidazol\n\ndihydro\n\npharmaceutical composition\n\nweight\n\npiperidine\n\nPrior art date\n\n2006-12-13\n\nLegal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)\n\nWithdrawn\n\nApplication number\n\nEP07123148A\n\nOther languages\n\nGerman (de)\n\nFrench (fr)\n\nOther versions\n\nEP1935412A2 (en\n\nEP1935412A9 (en\n\nInventor\n\nJÃ©rÃ´me BESSE\n\nCurrent Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)\n\nSUBSTIPHARM DEVELOPPEMENT\n\nGalenix Developpement\n\nOriginal Assignee\n\nGalenix Developpement\n\nPriority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)\n\n2006-12-13\n\nFiling date\n\n2007-12-13\n\nPublication date\n\n2011-05-04\n\n2007-12-13 Application filed by Galenix Developpement filed Critical Galenix Developpement\n\n2008-06-25 Publication of EP1935412A2 publication Critical patent/EP1935412A2/en\n\n2011-05-04 Publication of EP1935412A3 publication Critical patent/EP1935412A3/en\n\n2011-06-08 Publication of EP1935412A9 publication Critical patent/EP1935412A9/en\n\nStatus Withdrawn legal-status Critical Current\n\nLinks\n\nEspacenet\n\nEPO GPI\n\nEP Register\n\nGlobal Dossier\n\nDiscuss\n\nClassifications\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K9/00—Medicinal preparations characterised by special physical form\n\nA61K9/0012—Galenical forms characterised by the site of application\n\nA61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration\n\nA61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals\n\nLandscapes\n\nHealth & Medical Sciences (AREA)\n\nLife Sciences & Earth Sciences (AREA)\n\nVeterinary Medicine (AREA)\n\nZoology (AREA)\n\nNutrition Science (AREA)\n\nPhysiology (AREA)\n\nChemical & Material Sciences (AREA)\n\nMedicinal Chemistry (AREA)\n\nPharmacology & Pharmacy (AREA)\n\nEpidemiology (AREA)\n\nAnimal Behavior & Ethology (AREA)\n\nGeneral Health & Medical Sciences (AREA)\n\nPublic Health (AREA)\n\nPharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)\n\nMedicinal Preparation (AREA)\n\nAbstract\n\nLa prÃ©sente invention concerne une composition pharmaceutique, sous forme de comprimÃ© se dÃ©litant en moins de trois minutes, comprenant de 1% Ã 60% en poids du principe actif dompÃ©ridone ou d'un de ses sels pharmaceutiquement acceptables ; de 20% Ã 90% en poids d'au moins un agent diluant sans effet notoire ; de 0,01% Ã 5% d'au moins un agent mouillant ; de 0,1% Ã 15% en poids d'au moins un agent dÃ©sintÃ©grant ; les pourcentages en poids Ã©tant exprimÃ©s par rapport au poids total de ladite composition. La prÃ©sente invention concerne Ã©galement l'utilisation de ladite composition pharmaceutique pour la prÃ©paration d'un mÃ©dicament destinÃ© Ã traiter et/ou Ã prÃ©venir les nausÃ©es, les vomissements, les Ã©tats nausÃ©eux et/ou les troubles de la digestion et un procÃ©dÃ© de prÃ©paration d'un comprimÃ© orodispersible Ã base de ladite composition pharmaceutique.The present invention relates to a pharmaceutical composition, in the form of a tablet disintegrating in less than three minutes, comprising from 1% to 60% by weight of the active ingredient domperidone or a pharmaceutically acceptable salt thereof; from 20% to 90% by weight of at least one diluting agent with no known effect; from 0.01% to 5% of at least one wetting agent; from 0.1% to 15% by weight of at least one disintegrant; the percentages by weight being expressed relative to the total weight of said composition. The present invention also relates to the use of said pharmaceutical composition for the preparation of a medicament for treating and / or preventing nausea, vomiting, nausea and / or disorders of digestion and a method of preparing the same. an orodispersible tablet based on said pharmaceutical composition.\n\nEP07123148A 2006-12-13 2007-12-13 Pharmaceutical composition containing 5-chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-yl]-1,3-dihydro-2H-benzimidazol-2-one and method of preparing same Withdrawn EP1935412A3 (en)\n\nApplications Claiming Priority (1)\n\nApplication Number Priority Date Filing Date Title FR0655492A FR2909877B1 (en) 2006-12-13 2006-12-13 PHARMACEUTICAL COMPOSITION CONTENT OF 5-CHLORO-1- [1- [3- (2-OXO-2,3-DIHYDRO-1H-BENZIMIDAZOL-1-YL) PROPYL] PIPERIDIN-4-YL] -1,3-DIHYDRO -2H-BENZIMIDAZOL-2-ONE AND PROCESS FOR PREPARING THE SAME\n\nPublications (3)\n\nPublication Number Publication Date EP1935412A2 EP1935412A2 (en) 2008-06-25 EP1935412A3 true EP1935412A3 (en) 2011-05-04 EP1935412A9 EP1935412A9 (en) 2011-06-08\n\nFamily\n\nID=38650134\n\nFamily Applications (1)\n\nApplication Number Title Priority Date Filing Date EP07123148A Withdrawn EP1935412A3 (en) 2006-12-13 2007-12-13 Pharmaceutical composition containing 5-chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-yl]-1,3-dihydro-2H-benzimidazol-2-one and method of preparing same\n\nCountry Status (2)\n\nCountry Link EP (1) EP1935412A3 (en) FR (1) FR2909877B1 (en)\n\nFamilies Citing this family (1)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title CN110151711B (en) * 2019-04-25 2021-06-15 å¹¿ä¸äººäººåº·è¯ä¸æéå ¬å¸ Domperidone orally disintegrating tablet and preparation method thereof\n\nCitations (4)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title WO1996013251A1 (en) * 1994-10-28 1996-05-09 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms of hydrophobic substances WO2000007570A1 (en) * 1998-08-05 2000-02-17 The Boots Company Plc Pharmaceutical compositions comprising ibuprofen and domperidone EP1634586A1 (en) * 2004-09-09 2006-03-15 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Fast water-dispersible domperidone tablets WO2007104771A1 (en) * 2006-03-15 2007-09-20 Pierre Fabre Medicament Orodispersible domperidone tablets\n\nFamily Cites Families (3)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title FR2791569B1 (en) 1999-03-31 2003-05-09 Pf Medicament ISOTROPIC FAST DISSOLVING ISOTROPIC MICROPOROUS COMPOSITION OR STRUCTURE FOR PHARMACEUTICAL, VETERINARY, DIETETIC, FOOD OR COSMETIC USE AND PROCESS FOR OBTAINING THE SAME FR2845914B1 (en) 2002-10-18 2005-11-04 Schwarz Pharma Lab ANTIEMETIC COMPOUND WITH RAPID DISAGGREGATION CN1449757A (en) 2003-04-30 2003-10-22 æ±è¥¿çè¯ç©ç ç©¶æ Domperidone oral disintegrating tablet and preparation process thereof\n\n2006\n\n2006-12-13 FR FR0655492A patent/FR2909877B1/en active Active\n\n2007\n\n2007-12-13 EP EP07123148A patent/EP1935412A3/en not_active Withdrawn\n\nPatent Citations (4)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title WO1996013251A1 (en) * 1994-10-28 1996-05-09 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms of hydrophobic substances WO2000007570A1 (en) * 1998-08-05 2000-02-17 The Boots Company Plc Pharmaceutical compositions comprising ibuprofen and domperidone EP1634586A1 (en) * 2004-09-09 2006-03-15 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Fast water-dispersible domperidone tablets WO2007104771A1 (en) * 2006-03-15 2007-09-20 Pierre Fabre Medicament Orodispersible domperidone tablets\n\nAlso Published As\n\nPublication number Publication date FR2909877A1 (en) 2008-06-20 EP1935412A2 (en) 2008-06-25 FR2909877B1 (en) 2009-07-10 EP1935412A9 (en) 2011-06-08\n\nSimilar Documents\n\nPublication Publication Date Title WO2004033431A3 (en) 2004-07-29 Hydroxypyrazoles for use against metabolic-related disorders NO20073766L (en) 2007-09-21 Melted pyrazole derivatives and methods for the treatment of metabolic-related disorders thereof TNSN05109A1 (en) 2007-05-14 Deferasirox dispersible tablets TNSN06150A1 (en) 2007-11-15 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof WO2006070325A3 (en) 2006-09-14 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists WO2003037271A3 (en) 2003-10-16 Compounds, pharmaceutical compositions and methods of use therefor BG104877A (en) 2001-06-29 N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders CA2371940A1 (en) 2000-10-12 Pregelatinized starch in a controlled release formulation IE901051L (en) 1990-10-11 Use of indole derivatives as pharmaceuticals EP2008650A3 (en) 2011-04-27 Solid oral composition comprising a S 1 P receptor agonist and a sugar alcohol HUP0203870A2 (en) 2003-03-28 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist MA31072B1 (en) 2010-01-04 TETRAHYDROCYCLOPENTA [B] INDOLE COMPOUNDS AS MODULATORS OF THE ANDROGEN RECEPTOR WO2002019969A3 (en) 2002-07-11 (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents MA29451B1 (en) 2008-05-02 ASSOCIATION BETWEEN FERROQUIN AND AN ARTEMISININE DERIVATIVE FOR THE TREATMENT OF MALARIA CA2378369A1 (en) 2001-02-01 Small molecules useful in the treatment of inflammatory disease CA2378428A1 (en) 2001-02-15 Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes WO2005058890A3 (en) 2005-08-18 Hydronopol derivatives as agonists on human orl1 receptors EP1621198A3 (en) 2006-04-12 Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists EP0974363A4 (en) 2003-05-07 Remedies for drug addiction MA26732A1 (en) 2004-12-20 NOVEL PHARMACEUTICAL COMPOSITION COMPRISING AN OUR INHIBITOR, AND METHOD FOR THE PREPARATION THEREOF WO2004096118A3 (en) 2005-10-13 Composition for improving cognition and memory TW200519101A (en) 2005-06-16 Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors EP1935412A9 (en) 2011-06-08 Pharmaceutical composition containing 5-chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-yl]-1,3-dihydro-2H-benzimidazol-2-one and method of preparing same WO2003015690A3 (en) 2003-09-25 Method for treating primary insomnia FR2885807A1 (en) 2006-11-24 SOLID PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE OF 1- (2,3,4-TRIMETHOXYBENZYL) PIPERAZINE, AND PREPARATION METHOD\n\nLegal Events\n\nDate Code Title Description"
    }
}